MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

unresectable HCC

  • Home
  • unresectable HCC
Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma
Posted inClinical Updates news Oncology

Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma

Posted by By MedXY 09/20/2025
The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.
Read More
  • Distinct Molecular and Clinical Profiles of USH2A-Associated Retinitis Pigmentosa in Korean Patients: Implications for Targeted Therapy
  • Cystoid Macular Edema Following Cultured Human Corneal Endothelial Cell Injection: Incidence, Risk Factors, and Visual Prognosis
  • Post-Tonsillectomy Hemorrhage in Lebanon: Prevalence, Risks, and Implications for Adult Patients
  • Beta-Trace Protein Quantification: A Novel Diagnostic Tool for Early Detection of CSF Leak Post-Endoscopic Endonasal Sellar Tumor Surgery
  • Colovac Device vs Diverting Loop Ileostomy: A Prospective Pooled Analysis in Rectal Cancer Surgery
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top